Vir Bio Q1 net loss $125.7M; cash $809.3M; positive CHD data; VIR-5500 collaboration closed

Vir Biotechnology, Inc.

2026-Q1 EPS reported -$0.85 revenue$-29,000

Net loss of $125.7M ($0.85 per share) vs $121M ($0.88) in Q1 2025.
Cash, cash equivalents, and investments $809.3M at March 31, 2026; plus $315M Astellas upfront and equity in Q2.
Phase 2 SOLSTICE: 77% (24/31) HDV RNA undetectable at Week 72, rising to 88% (21/24) at Week 96.
Phase 3 ECLIPSE 1 topline data expected Q4 2026; ECLIPSE 2/3 in Q1 2027.
Completed $172.5M public offering; closed Astellas collaboration for VIR-5500; first patient dosed in Phase 1 expansion.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Vir Biotechnology, Inc. reported the first quarter ended March 31, 2026 results: net income Net loss for the first quarter of 2026 was $125.7 million, or $0.85 per share, basic and diluted, EPS $0.85 per share, basic and diluted.

Period: the first quarter ended March 31, 2026
Net income: Net loss for the first quarter of 2026 was $125.7 million, or $0.85 per share, basic and diluted
EPS: $0.85 per share, basic and diluted
Result: reported results

Exact text from the filing

On May 6, 2026, Vir Biotechnology, Inc. (the Company) issued a press release announcing its financial results for the quarter ended March 31, 2026.

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

Vir Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-031273

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.